Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases
Inmaculada Rapado(Wellcome Sanger Institute), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), José‐Ángel Hernández‐Rivas(Hospital Universitario Infanta Leonor), Silvia Grande(Research Institute Hospital 12 de Octubre), Enriqueta Albízua(Hospital Universitario HM Madrid), Florinda Gilsanz(Hospital Universitario HM Madrid), Luis García‐Alonso(Instituto de Neurociencias), Rosa Ayala(Hospital Universitario 12 De Octubre), Miguel Gallardo(Spanish National Cancer Research Centre)
Cited by 37
Related Papers
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523